伐地那非治疗勃起失调（ED）

阴蒂病变（ED）病患者状愈来愈偏爱可用Vardenafil（魏地那非）进行放射治疗对ED药品Sildenafil（西地那非）和Vardenafil（魏地那非）进行偏爱来得科学实验，想要只能取得无种族歧视的结果。波士顿-2006年9翌年20日，研究成果结果发表在《病态Journal》上，同时在埃及开罗召开的病态医学国际协则会第十二届大则会上发布。这项研究成果极其契合，因为其数据来自一项关于PDE5（氨基二脂酶5）同样病态药品的单独对比乳癌，该试制可用PDE5同样病态药品来放射治疗ED病患者状。整个研究成果经过除此以外使得针对每种药品的种族歧视超过消除。这是一项随机、随机对照、交叉和单独对比的乳癌，可用西地那非和魏地那非放射治疗抑郁病患者ED、心肌梗死、心肌梗死和/或高血脂的年长者病患者状，来得了二者的治镇痛果。结果显示在数个近似于的理论上称之为标上魏地那非获取了统计学含意上的优势，在病者调查结果和偏爱病态的多个风险评估飞行测试当中，魏地那非的展示出比起西地那非差。分别为1，057名年长者参与了这项研究成果，他们首先不间断四个星期施用一种药品，然后是一个星期时间段的缓冲期，接着再次不间断四个星期施用另一种药品。病者则会被曾说这样的问题：“总的来曾说，你愈来愈喜欢可用那种药品？”此外还有其他11个有关ED放射治疗镇痛的问题。利用原本常规进行附加理论上风险评估在分析当中也被可用。数据显示38.9%的病者偏爱可用魏地那非，而34.5%的病者愿意可用西地那非（26.6%的病者无偏爱病态）。在阴蒂功能，病态交调查结果和整体而言调查结果方面，魏地那非相当大很低西地那非。在阴蒂时插入硬度，阴蒂保有时间段，全程保有和阴蒂自信方面，魏地那非也有愈来愈高比则有的阳病态反应。这项研究成果的共同著者，病态Journal的主编Irwin Goldstein 阐释曾说：“该研究成果指成我们对PDE5同样病态药品诊断分野的理解又前进了重要一步，肯定了魏地那非放射治疗ED的镇痛。”目前为止有三种PDE5同样病态药品可用于放射治疗ED，它们分别是西地那非，他远超那非和魏地那非。根据研究成果者的曾说法，所有这三种药品对一定之内的人群都展示出成理论上和抗病态。来自单独对比的诊断科学实验数据（如本项研究成果）极其较多，然而这样的研究成果结果则会希望诊断医生对西地那非、魏地那非和他远超那非加以分野以同样最适合的药品专供生殖病病患者状可用。背景知识：ED：阴蒂病变 Erectile dysfunction, ED是称之为乳房停滞不用超过或者保有阴蒂以依赖于病态生活。ED比只不过用的"阳萎"（Impotence）一词愈来愈确切，因为癫痫一词带有一定歧病态的字眼。ED可按其程度分为重为、当中、重三度，癫痫归属于重度的ED。70二十世纪后由于阴蒂环境因素和病病患者研究成果的进展，人们体认到固然焦虑因素确实可以产生ED，但对大多数年长者来曾说，ED与许多营养不良（心肌梗死，心肌梗死，心血管营养不良）、药品、外伤及移植手术等有关，因为阴蒂机制是乳房角质层黏膜松弛，乳房静脉缩减张，脏器减小和静脉回流受阻等完整血清动力学步骤，在这一步骤当中，任何病变的哮喘可以分为： 器质病态ED 乳癌诱因：包括任何似乎随之而来乳房角质层静脉脏器减少的营养不良，如：静脉粥样硬化，静脉受损，静脉狭窄，生殖器静脉分段及心功能异常等，或不利于静脉回流的环机制的乳房白膜、乳房海绵窦内黏膜减少主因的乳房静脉残。 神经病态诱因：当本部、向外神经营养不良或受损均可以随之而来阴蒂病变。 移植手术与外伤：大血管移植手术、乳腺癌根治术、褐则阴蒂直肠癌根治术等移植手术及骨盆骨折、椎间盘压缩病态骨折或驾跨伤，可以产生乳房起有关的血管和神经受损，随之而来阴蒂病变。 遗传病态帕金森氏病患者、慢病态病和长期施用某些药品也可以产生阴蒂病变。 乳房本身营养不良：如乳房硬结病患者（Peyronie's disease）、乳房突起畸形、严重影响背痛和包皮放养龟头炎。 焦虑病态ED 称之为缓和、压力、抑郁、焦虑和夫妻感情不和等信念焦虑因素所产生的阴蒂病变。 混合病态ED 称之为信念焦虑因素和器质病态哮喘共同随之而来的阴蒂病变。此外，由于器质病态ED没取得及时的放射治疗病患者状焦虑压力加重，怨恨病态交失利，使ED放射治疗愈来愈加趋向复杂。国内一组628则有ED病患者状哮喘定义的研究成果指成：焦虑病态九成39%。器质病态为15.8%，混合病态九成45.2%。PDE5同样病态剂PDE5是角质层当中黏膜蛋白质第二信使NO-cGMP的分解酶。PDE5同样病态剂只能减小cGMP的浓度，增强角质层黏膜的麻痹作用，并促进病态刺激诱发的阴蒂反应。PDE5同样病态剂吗啡对ED放射治疗具有最国际上的理论上和抗病态。因此，该吗啡被看成制剂放射治疗药品镇痛的参照常规。目前为止，该吗啡包括三种：西地那非、魏地那非和他远超里斯非。西地那非在1998年，魏地那非和他里斯那非则是在2003年取得全球认证。在诊断可用以及诊断比对研究成果当中注意到，PDE5同样病态剂具有良好的抗病态和理论上。在一般而言ED病患者状当中，诊断研究成果充分证实上述三种药品的理论上。 Study shows men with ED favor treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON ---- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in analysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors available to treat ED: sildenafil, tadalafil and vardenafil, all of which have previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.主笔：bluelove

主笔： Zhu